BioSpace News Archive

These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation Annual Congress in Abu Dhabi today.

The results from the 1,206 patient study found that ABRAXANE demonstrated a significantly higher disease-free survival rate, a secondary efficacy endpoint, in high risk early breast cancer patients when compared to conventional solvent-based paclitaxel.

Following on from its recent CE Mark approval, which enables Atomo to market the product in Europe, the ERP-D approval will facilitate further expansion and commercial roll-out of the product in LMICs.

Mr. Capdevielle is a seasoned executive with over 37 years of international experience and has a successful track record of helping startup companies.

In this role, Dr. Walsh will direct and manage the N&I Medical Affairs team to develop and implement plans for Rebif and our products in development, both in the US and in collaboration with Global Medical Affairs.

Effective January 1, 2018, providers will receive increased payments from Medicare for the StimRouter implant procedure, making the device an even more viable pain management option for patients and physicians nationwide.

Syros announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response.

AmerisourceBergen announced today a commitment to a set of ongoing operating principles in order to further support the Company’s efforts to address opioid diversion and abuse.

The agreement allows Ortho to use the sphingotest bio-ADM immunoassay on Ortho’s automated VITROS Immunodiagnostics and Integrated Systems for small, mid- and high-volume clinical laboratories.

Existing and new investors, including Launch Capital and BlueIO participated in the financing.